This is a cross-sectional, observational study. This study is for subjects with specific histologically confirmed malignancies
Cancer subjects will undergo testing of their tumor tissue for tumor antigen expression, which may consist of the submission of an archived or fresh tumor specimen for appropriate testing. For instance, subjects who may be considering enrollment in a trial involving rovalpituzumab tesirine, an antibody-drug conjugate targeting delta-like protein 3 (DLL3), will undergo tumor expression testing for DLL3 by immunohistochemistry (IHC). Subjects may be observed for progression and survival.
The investigator and subject will be made aware of the results of this testing, to guide consideration for clinical research protocols where interventions include the use of testing for target specific tumor antigens.
The purpose of this study is to learn about the safety and effectiveness of the investigational (not yet approved by the FDA) study drug, PF-04136309, when given in combination with nab-paclitaxel plus gemcitabine, and to find the best dose for treating metastatic pancreatic cancer.
Nab-paclitaxel and gemcitabine are approved in the United States and are available by prescription for metastatic pancreatic cancer. However, the use of nab-paclitaxel and gemcitabine in combination with PF-04136309 are investigational in this research study because they are not currently approved to metastatic pancreatic cancer in combination with PF 04136309.
This research study will be conducted in 2 parts as a Phase 1b (Part 1) and Phase 2 (Part 2).
In Phase 1, different doses of PF-04136309 in combination with nab-paclitaxel plus gemcitabine will be used in a small group of patients in order to determine the highest safe dose that can be taken and to select the dose that will be used for the next part of the study, Phase 2.
The study is sponsored by Pfizer. The investigator in charge of this study is Carolyn Britten. For Phase 1b (Part 1), there will be up to about 20 people at least 18 years old enrolled in this study. The study is being done at about 4 different research sites in the United States. About 2 to 4 people will be enrolled at MUSC.
Our belief is that point-of-care ultrasound has not transcended into the nurse practitioner?s clinical practice in the form of formal or informal training. This survey aims to determine the accessibility to and utility of point-of-care ultrasound amongst nurse practitioners for patient evaluation as well as gauge their interest in formalized training.
The purpose of this study is to evaluate the progression free survival (PFS) , based on investigator radiologic review, of AGS-16C3F compared to axitinib in adult subjects with metastatic renal cell carcinoma. The time frame for PFS is 24 months.
This is a multi-institutional, randomized, placebo controlled, double-blinded phase II trial of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer who have achieved at least stable disease on first-line chemotherapy.
This study is for patients that have been diagnosed with acute myeloid leukemia with mutations in the Fms-like tyrosine kinase receptor (FLT3). The investigational drug in this study is midostaurin. The purpose of this study is to provide access to midostaurin and gather additional safety data on the combination of midostaurin and standard chemotherapy in subjects 18 years of age, or older, with newly diagnosed AML that have a FLT3 mutation (ITD or TKD). Participants can expect to be in this study for about 1 year.
The goal of this study is to determine the safety and efficacy of a chemotherapy regimen known as Modified FOLFIRINOX (mFFX) alone or with the addition of Stereotactic Body Radiotherapy (SBRT). SBRT is a type of highly focused and precise x-ray treatment done in a total of 5 treatments. We hope to learn if this new treatment combination helps to control the disease and improve survival for patients with locally advanced pancreatic cancer.
This study is for patients that have been diagnosed with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The investigational drug in this study is MEDI4736, tremelimumab and AZD9150. The purpose of this study is designed to find out the best dose of experimental drugs called MEDI4736, tremelimumab and AZD9150. The research study will also investigate how safe MEDI4736 is when given alone or together with tremelimumab or AZD9150 in participants with DLBCL. Participants can expect to be in this study for up to 4 years.
The goal of this study is to receive Veteran feedback on an intervention being developed for female Veterans to reduce their risk of alcohol misuse and sexual assault. We are recruiting 20 female Veterans who engage in alcohol misuse to receive feedback on the intervention content. Feedback will be integrated into the intervention prior to being used with female Veterans.
The purpose of this study is to test study treatments that combine an investigational drug (ONT-380) with two approved drugs (capecitabine and trastuzumab) in subjects with advanced breast cancer to find out what effects, good or bad, it may have on you and your disease.